Evidence map›Paper›PMID 28843675›Full record

ArticleRespiratory physiology & neurobiology2018

Aerosol furosemide for dyspnea: High-dose controlled delivery does not improve effectiveness.

Robert B Banzett, Richard M Schwartzstein, Robert W Lansing, Carl R O'Donnell

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory physiology & neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Is Inhaled Furosemide a Potential Therapeutic for COVID-19?The American journal of the medical sciences · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Robert B BanzettDivision of Pulmonary, Critical Care, and Sleep Medicine Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA. Electronic address: rbanzett@bidmc.harvard.edu.
Richard M SchwartzsteinDivision of Pulmonary, Critical Care, and Sleep Medicine Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.
Robert W LansingDivision of Pulmonary, Critical Care, and Sleep Medicine Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
Carl R O'DonnellDivision of Pulmonary, Critical Care, and Sleep Medicine Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.
Beth Israel Deaconess Medical Center · US

Funding

Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
AEROSOL FUROSEMIDE FOR DYSPNEA RELIEF: LABORATORY AND CLINICAL STUDIESR01NR012009 · NINR · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BANZETT, ROBERT B · 2011 to 2015
$2.3M
NCATS NIH HHS UL1 TR000170NINR NIH HHS R01 NR012009
6 · The paper itself

Abstract

Published studies have shown great variability in response when aerosolized furosemide has been tested as a palliative treatment for dyspnea. We hypothesized that a higher furosemide dose with controlled aerosol administration would produce consistent dyspnea relief. We optimized deposition by controlling inspiratory flow (300-500mL/s) and tidal volume (15% predicted vital capacity) while delivering 3.4μm aerosol from either saline or 80mg of furosemide. We induced dyspnea in healthy subjects by varying inspired PCO

Indexed as

Administration, InhalationAdolescentAdultAerosolsAlbuterolDose-Response Relationship, DrugDyspneaFemaleFurosemideHumansInhalationMaleModels, BiologicalPain MeasurementPalliative CareSodium Potassium Chloride Symporter InhibitorsAerosolsAlbuterolFurosemideSodium Potassium Chloride Symporter InhibitorsDyspneaFurosemidePalliative careSymptom management

Identifiers

PMID28843675
PMCPMC6358582
OpenAlexW2748527190

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.